MoonLake Immunotherapeutics (MLTX) — Cash Flow Reinvestment Rate
Latest as of June 2021:
2.61x
MoonLake Immunotherapeutics (MLTX) has a Cash Flow Reinvestment Rate of 2.61x as of June 2021, reinvesting $16.01K (capex $16.01K ) from operating cash flow of $6.14K. See cash generation quality of MoonLake Immunotherapeutics to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
2.61x
(Capex + Investments) / Operating CF
Total Reinvested
$16.01K
Capex + Investments
Operating Cash Flow
$6.14K
USD
Capital Expenditures
$16.01K
USD
Annual Cash Flow Reinvestment Rate for MoonLake Immunotherapeutics (None–None)
Year-by-year capital reinvestment analysis for MoonLake Immunotherapeutics. See MLTX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow